Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
about
Oncolytic virotherapy for pediatric malignancies: future prospectsObatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection.Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.Impact of tumor microenvironment on oncolytic viral therapyThe combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.Incomplete but infectious vaccinia virions are produced in the absence of oncolysis in feline SCCF1 cells.Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice.Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation.Features of the Antitumor Effect of Vaccinia Virus Lister StrainSafety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory BeaglesOn the potential of oncolytic virotherapy for the treatment of canine cancers.Targeting tumor vasculature through oncolytic virotherapy: recent advances.Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunityAn infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors.Oncolytic vaccinia virus for the treatment of cancer.Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?Update on oncolytic viral therapy - targeting angiogenesisT-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.GMCSF-armed vaccinia virus induces an antitumor immune response.Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain.Advances in the mechanisms of action of cancer-targeting oncolytic viruses.Synergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virus
P2860
Q28069358-04332519-4D13-4FE5-B934-CDB678AD6F30Q30448355-947F662B-F2C6-4CD8-B57F-D21D1A8AE5F9Q33769835-0A6D81A7-FA9F-4CD5-AC86-CEAA6FBD29FCQ33895533-6B4EBA5D-8D20-4211-9338-349DFD5A0C9DQ34316241-9E266E0A-57CD-491C-A725-257A2817DC0CQ35584276-9048B374-A768-47B0-A954-8FA4FCED2052Q35623101-67236C54-BD38-4773-A562-C385A18CF212Q36099082-1FD92097-1789-4B0D-B942-8FA12951F12EQ36237474-F48A5EC6-DC25-4429-B79A-AC11D8CAAD39Q36507293-BA8F0BD5-45C8-46F7-9B75-D77A58FE6F0CQ36664201-F6500B12-65B5-4ADA-AF4B-EED02748DEBFQ37031925-48292854-CE78-4793-B9C4-D92F52D7439CQ37031932-7CB0DEB1-E7F4-4AE4-931E-1AD80FAF1B0EQ37225198-CBACAD61-B167-4AEE-BBD5-6A275192C1E6Q37316842-F046E5A3-3259-43D2-98C9-8DA1AF104D17Q37845399-809F1708-B6D4-4DC2-844F-F9990B0C9001Q38008023-5808059E-9AD6-4121-8765-458ED6520306Q38128561-06D3CA40-16F7-441A-B588-33A59D428F5AQ38648630-0380819C-0E92-42F9-BDF9-10A055E1FE83Q38673968-014E2465-6E60-4DCD-B43E-365D30CC94C7Q38924539-D5A58E68-F2BB-4C71-8DB2-CF480CB91D9DQ41706553-DB2A3201-94DF-4322-A1D7-304CA478F3F8Q42205083-3E9CB8C1-1AC6-4535-8AFF-F4B474F84373Q42280873-1A00FB2C-634B-4C41-AB15-05DC4D4DFB09Q42795549-FF7D45F6-B3C9-479B-87B1-8B3F138AE39AQ52655195-4F01779D-CF64-4895-9809-D16A2492383EQ58565390-B9593247-8089-4134-ABA3-9C2C2F246F03
P2860
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Antiangiogenic arming of an on ...... y in renal cell cancer models.
@ast
Antiangiogenic arming of an on ...... y in renal cell cancer models.
@en
Antiangiogenic arming of an on ...... y in renal cell cancer models.
@nl
type
label
Antiangiogenic arming of an on ...... y in renal cell cancer models.
@ast
Antiangiogenic arming of an on ...... y in renal cell cancer models.
@en
Antiangiogenic arming of an on ...... y in renal cell cancer models.
@nl
prefLabel
Antiangiogenic arming of an on ...... y in renal cell cancer models.
@ast
Antiangiogenic arming of an on ...... y in renal cell cancer models.
@en
Antiangiogenic arming of an on ...... y in renal cell cancer models.
@nl
P2093
P2860
P50
P356
P1433
P1476
Antiangiogenic arming of an on ...... y in renal cell cancer models.
@en
P2093
Ari Ristimäki
Fabrice Le Boeuf
J Andrea McCart
Kathryn Ottolino-Perry
Kilian Guse
Marta Sloniecka
Sari Pesonen
P2860
P304
P356
10.1128/JVI.00692-09
P577
2009-11-11T00:00:00Z